Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers

dc.authoridharputluoglu, hakan/0000-0001-8537-5941
dc.authoridBaykara, Meltem/0000-0003-3291-8134
dc.authoridbenekli, mustafa/0000-0003-3184-4946
dc.authoridÖksüzoğlu Çakmak, Ömür Berna/0000-0002-2756-8646
dc.authoridSevinç, Alper/0000-0002-0499-8918
dc.authoridAkinci, Muhammed Bulent/0000-0001-7575-9925
dc.authoridDEMIRCI, UMUT/0000-0002-4833-6721
dc.authorwosidharputluoglu, hakan/ABI-6451-2020
dc.authorwosidSevinc, Alper/KFQ-6440-2024
dc.authorwosidBaykara, Meltem/G-8211-2014
dc.authorwosidÖzet, ahmet/ABC-9831-2021
dc.authorwosidbenekli, mustafa/AAE-4555-2020
dc.authorwosidÖksüzoğlu Çakmak, Ömür Berna/HKN-6428-2023
dc.authorwosidYalcin, Bulent/HIK-0062-2022
dc.contributor.authorBaykara, Meltem
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorEkinci, Ozgur
dc.contributor.authorIrkkan, Sultan Cigdem
dc.contributor.authorKaraca, Halit
dc.contributor.authorDemirci, Umut
dc.contributor.authorAkinci, Muhammed Bulent
dc.date.accessioned2024-08-04T20:41:08Z
dc.date.available2024-08-04T20:41:08Z
dc.date.issued2015
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIn this study, we investigated the rate of human epidermal growth factor receptor 2 (HER2) overexpression in gastric (GC) and gastroesophageal junction cancers (GEJCs) and the relationship with HER2 expression and clinical, pathological parameters and prognosis. Surgery or biopsy specimen of 598 (436 males, 162 females) patients with GC or GEJC was evaluated for the presence of HER2 overexpression by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) methods. HER2 IHC scores were as follows: 418 (69.9 %) IHC 0, 58 (9.7 %) IHC 1+, 50 (8.4 %) IHC 2+, 72 (12 %) IHC 3+. Among 50 patients with IHC 2+, 18 (38.2 %) were FISH positive, and 29 (61.7 %) were FISH negative for HER2 amplification. Patients were regarded as HER2 positive in case of IHC 3+ disease or IHC 2+ disease with a positive FISH test result for HER2 amplification. In the primary analysis population, 90 (15 %) were considered HER2 positive. HER2 positivity was higher in intestinal GC compared to diffuse GC (16.9 vs 6.6 %, p = 0.014). HER2 positivity was significantly higher in well and moderately differentiated tumors than poorly differentiated tumors (p < 0.0001). HER2 positivity had no significant effect on median OS (23.2 vs 19.1 months, p = 0.44). But in the early stages (stages I and II), median OS of HER2-positive patients was shorter than HER2-negative patients (51.4 months vs not reach, p = 0.047). However, median OS was similar in patients with advanced stages (stages III and IV) HER2-positive and HER2-negative disease (16.2 vs 13.7 months, p = 0.72). Rate of HER2 positivity is similar in Turkish patients with GC and GEJCs. HER2 positivity is associated with poor prognosis in patients with early-stage disease.en_US
dc.identifier.doi10.1007/s11605-015-2888-y
dc.identifier.endpage1571en_US
dc.identifier.issn1091-255X
dc.identifier.issn1873-4626
dc.identifier.issue9en_US
dc.identifier.pmid26179664en_US
dc.identifier.scopus2-s2.0-84939466651en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1565en_US
dc.identifier.urihttps://doi.org/10.1007/s11605-015-2888-y
dc.identifier.urihttps://hdl.handle.net/11616/96931
dc.identifier.volume19en_US
dc.identifier.wosWOS:000359934200001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Gastrointestinal Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGCen_US
dc.subjectGEJCsen_US
dc.subjectHER2en_US
dc.subjectPrognosisen_US
dc.titleClinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancersen_US
dc.typeArticleen_US

Dosyalar